1. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma.
- Author
-
Liu WL, Zhang G, Wang JY, Cao JY, Guo XZ, Xu LH, Li MZ, Song LB, Huang WL, and Zeng MS
- Subjects
- Antibodies, Neoplasm immunology, Antibody Formation, Autoantibodies immunology, Biomarkers, Tumor immunology, Carcinoma, Squamous Cell blood, Carcinoma, Squamous Cell immunology, Esophageal Neoplasms blood, Esophageal Neoplasms immunology, Humans, Antibodies, Neoplasm blood, Autoantibodies blood, Biomarkers, Tumor blood, Carcinoma, Squamous Cell diagnosis, Esophageal Neoplasms diagnosis, Proteomics, cdc25 Phosphatases immunology
- Abstract
This study was aimed to identify tumor proteins that elicit a humoral response in patients with esophageal squamous cell carcinoma (ESCC). Autologous sera of 15 newly diagnosed patients with ESCC and age- and gender-matched 15 healthy controls were analyzed individually for antibody-based reactivity against proteins from 15 homogenized ESCC tissue mixture resolved by two-dimensional PAGE. One protein spot, which reacted with sera from ESCC patients but not with those from controls, was identified to be CDC25B by mass spectrometry and Western blotting. High expression of CDC25B was detected in ESCC cell lines and primary tumor tissues, but not in normal esophageal tissues. In addition, CDC25B expression was significantly higher in tumor tissue of patients with sera positive CDC25B-Abs than that of patients without CDC25B-Abs. Finally, anti-CDC25B antibodies were readily detectable in sera from 45 of 124 (36.29%) patients with ESCC, 13 of 150 (8.67%) patients with other types of cancer and 0 of 102 (0%) of healthy individuals. Thus, CDC25B autoantibodies may have clinical utility in ESCC screening and diagnosis.
- Published
- 2008
- Full Text
- View/download PDF